UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 15, 2005
PerkinElmer, Inc.
(Exact Name of Registrant as Specified in Charter)
| Massachusetts | 001-05075 | 04-2052042 | ||
(State or Other Jurisdiction of Incorporation | (Commission File Number) | (IRS Employer Identification No.) |
| 45 William Street, Wellesley, Massachusetts | 02481 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (781) 237-5100
Not applicable.
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
In September 2005, the Company approved a plan to sell its Fluid Sciences business. Accordingly, the results of operations have been segregated from continuing operations and reported in a separate line on the Company’s Consolidated Income Statements. The following schedules were prepared in order to provide the Company’s investors and the analyst community with detail on the operations of the Fluid Sciences business. These schedules reconcile the Consolidated Income Statements prepared in accordance with generally accepted accounting principals (“GAAP”) and included in our periodic filings to non-GAAP Pro Forma Income Statements which present consolidated operations to include Fluid Sciences as continuing operations. The reconciliations were provided for each of the three quarters for the nine months ended September 26, 2004 and for the nine months ended October 2, 2005.
The Company’s management believes that presentation of this information for Fluid Sciences provides useful information to investors regarding our financial condition and results of operations because it helps investors gain a meaningful understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such results to previous periods or forecasts. The Company’s management uses this information to assist in their financial and operational decision-making.
| Q1 2005 QTD | Q1 2004 QTD | ||||||||||||||
| Consolidated Income Statement | Fluid Sciences | Pro Forma Income Statement with Fluid Sciences | Consolidated Income Statement | Fluid Sciences | Pro Forma Income Statement with Fluid Sciences | ||||||||||
Sales Total | 361,167 | 54,721 | 415,888 | 334,778 | 57,487 | 392,265 | |||||||||
Cost of Sales | 205,445 | 41,141 | 246,586 | 196,918 | 42,536 | 239,454 | |||||||||
Research & Development | 22,709 | 870 | 23,579 | 19,250 | 627 | 19,877 | |||||||||
In-Process Research & Development | 194 | 0 | 194 | 0 | 0 | 0 | |||||||||
Selling, General and Administrative Expenses | 97,303 | 4,904 | 102,207 | 89,826 | 5,134 | 94,960 | |||||||||
Amortization of Intangible Assets | 7,113 | 220 | 7,333 | 6,881 | 220 | 7,101 | |||||||||
Operating Income from Continuing Operations | 28,403 | 7,586 | 35,989 | 21,903 | 8,970 | 30,873 | |||||||||
Interest and other expense, net | 8,088 | 190 | 8,278 | 9,093 | 443 | 9,536 | |||||||||
Income from continuing operatings before income taxes | 20,315 | 7,396 | 27,711 | 12,810 | 8,527 | 21,337 | |||||||||
Provision (benefit) for income taxes | 4,907 | 2,661 | 7,568 | 2,924 | 3,204 | 6,128 | |||||||||
Income from Continuing Operations | 15,408 | 4,735 | 20,143 | 9,886 | 5,323 | 15,209 | |||||||||
Income (Loss) from Discontinued Operations, net | 4,343 | (392 | ) | 3,583 | (1,740 | ) | |||||||||
Gain (Loss) on Disposition of Discontinued Operations, net | 77 | 77 | (198 | ) | (198 | ) | |||||||||
Net Income | 19,828 | 19,828 | 13,271 | 13,271 | |||||||||||
Diluted Earnings (Loss) Per Share: | |||||||||||||||
Continuing Operations | 0.12 | 0.04 | 0.15 | 0.08 | 0.04 | 0.12 | |||||||||
Income (Loss) from Discontinued Operations, net | 0.03 | 0.00 | 0.03 | (0.01 | ) | ||||||||||
Gain (Loss) on Disposition of Discontinued Operations, net | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
Net Income Per Share | 0.15 | 0.15 | 0.10 | 0.10 | |||||||||||
Weighted average diluted shares of common stock outstanding | 131,056 | 131,056 | 131,056 | 128,933 | 128,933 | 128,933 | |||||||||
| Q2 2005 QTD | Q2 2004 QTD | ||||||||||||||
| Consolidated Income Statement | Fluid Sciences | Pro Forma Income Statement with Fluid Sciences | Consolidated Income Statement | Fluid Sciences | Pro Forma Income Statement with Fluid Sciences | ||||||||||
Sales Total | 369,202 | 56,344 | 425,546 | 352,017 | 60,063 | 412,080 | |||||||||
Cost of Sales | 211,062 | 43,509 | 254,571 | 201,616 | 43,890 | 245,506 | |||||||||
Research & Development | 22,157 | 743 | 22,900 | 21,063 | 476 | 21,539 | |||||||||
Selling, General and Administrative Expenses | 93,424 | 4,646 | 98,070 | 91,570 | 5,644 | 97,214 | |||||||||
Restructuring & Asset Impairment | 14,245 | 690 | 14,935 | 0 | 0 | 0 | |||||||||
Amortization of Intangible Assets | 7,180 | 220 | 7,400 | 6,857 | 220 | 7,077 | |||||||||
Operating Income from Continuing Operations | 21,134 | 6,536 | 27,670 | 30,911 | 9,833 | 40,744 | |||||||||
Interest and other expense, net | 7,450 | 441 | 7,891 | 9,611 | 250 | 9,861 | |||||||||
Income from continuing operatings before income taxes | 13,684 | 6,095 | 19,779 | 21,300 | 9,583 | 30,883 | |||||||||
(Benefit) Provision for income taxes | (16,522 | ) | 2,192 | (14,330 | ) | 5,095 | 3,609 | 8,704 | |||||||
Income from Continuing Operations | 30,206 | 3,903 | 34,109 | 16,205 | 5,974 | 22,179 | |||||||||
Income (Loss) from Discontinued Operations, net | 3,494 | (409 | ) | 4,630 | (1,344 | ) | |||||||||
(Loss) Gain on Disposition of Discontinued Operations, net | (4,802 | ) | (4,802 | ) | 0 | 0 | |||||||||
Net Income | 28,898 | 28,898 | 20,835 | 20,835 | |||||||||||
Diluted Earnings (Loss) Per Share: | |||||||||||||||
Continuing Operations | 0.23 | 0.03 | 0.26 | 0.13 | 0.05 | 0.17 | |||||||||
Income (Loss) from Discontinued Operations, net | 0.03 | 0.00 | 0.04 | (0.01 | ) | ||||||||||
(Loss) Gain on Disposition of Discontinued Operations, net | (0.04 | ) | (0.04 | ) | 0.00 | 0.00 | |||||||||
Net Income Per Share | 0.22 | 0.22 | 0.16 | 0.16 | |||||||||||
Weighted average diluted shares of common stock outstanding | 130,718 | 130,718 | 130,718 | 129,362 | 129,362 | 129,362 | |||||||||
| Q3 2005 QTD | Q3 2004 QTD | ||||||||||||||
| Consolidated Income Statement | Fluid Sciences | Pro Forma Income Statement with Fluid Sciences | Consolidated Income Statement | Fluid Sciences | Pro Forma Income Statement with Fluid Sciences | ||||||||||
Sales Total | 361,901 | 58,271 | 420,172 | 341,601 | 61,089 | 402,690 | |||||||||
Cost of Sales | 204,510 | 43,977 | 248,487 | 198,567 | 44,250 | 242,817 | |||||||||
Research & Development | 21,808 | 692 | 22,500 | 20,435 | 759 | 21,194 | |||||||||
Selling, General and Administrative Expenses | 87,722 | 4,250 | 91,972 | 83,430 | 4,811 | 88,241 | |||||||||
Amortization of Intangible Assets | 7,159 | 220 | 7,379 | 6,920 | 220 | 7,140 | |||||||||
Operating Income from Continuing Operations | 40,702 | 9,132 | 49,834 | 32,249 | 11,049 | 43,298 | |||||||||
Interest and other expense, net | 6,093 | 505 | 6,598 | 8,030 | 477 | 8,507 | |||||||||
Income from continuing operatings before income taxes | 34,609 | 8,627 | 43,236 | 24,219 | 10,572 | 34,791 | |||||||||
Provision for income taxes | 8,464 | 3,103 | 11,567 | 5,825 | 3,979 | 9,804 | |||||||||
Income from Continuing Operations | 26,145 | 5,524 | 31,669 | 18,394 | 6,593 | 24,987 | |||||||||
Income (Loss) from Discontinued Operations, net | 5,500 | (24 | ) | 5,889 | (704 | ) | |||||||||
Gain (Loss) on Disposition of Discontinued Operations, net | 188 | 188 | (269 | ) | (269 | ) | |||||||||
Net Income | 31,833 | 31,833 | 24,014 | 24,014 | |||||||||||
Diluted Earnings (Loss) Per Share: | |||||||||||||||
Continuing Operations | 0.20 | 0.04 | 0.24 | 0.14 | 0.05 | 0.19 | |||||||||
Income (Loss) from Discontinued Operations, net | 0.04 | 0.00 | 0.05 | (0.01 | ) | ||||||||||
Gain (Loss) on Disposition of Discontinued Operations, net | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
Net Income Per Share | 0.24 | 0.24 | 0.19 | 0.19 | |||||||||||
Weighted average diluted shares of common stock outstanding | 131,291 | 131,291 | 131,291 | 129,395 | 129,395 | 129,395 | |||||||||
| Q3 2005 YTD | Q3 2004 YTD | |||||||||||||||
| Consolidated Income Statement | Fluid Sciences | Pro Forma Income Statement with Fluid Sciences | Consolidated Income Statement | Fluid Sciences | Pro Forma Income Statement with Fluid Sciences | |||||||||||
Sales Total | 1,092,270 | 169,336 | 1,261,606 | 1,028,396 | 178,639 | 1,207,035 | ||||||||||
Cost of Sales | 621,017 | 128,627 | 749,644 | 597,101 | 130,676 | 727,777 | ||||||||||
Research & Development | 66,674 | 2,305 | 68,979 | 60,748 | 1,862 | 62,610 | ||||||||||
In-Process Research & Development | 194 | 0 | 194 | 0 | 0 | 0 | ||||||||||
Selling, General and Administrative Expenses | 278,449 | 13,800 | 292,249 | 264,826 | 15,589 | 280,415 | ||||||||||
Restructuring & Asset Impairment | 14,245 | 690 | 14,935 | 0 | 0 | 0 | ||||||||||
Amortization of Intangible Assets | 21,452 | 660 | 22,112 | 20,658 | 660 | 21,318 | ||||||||||
Operating Income from Continuing Operations | 90,239 | 23,254 | 113,493 | 85,063 | 29,852 | 114,915 | ||||||||||
Interest and other expense, net | 21,631 | 1,136 | 22,767 | 26,734 | 1,170 | 27,904 | ||||||||||
Income from continuing operatings before income taxes | 68,608 | 22,118 | 90,726 | 58,329 | 28,682 | 87,011 | ||||||||||
(Benefit) Provision for income taxes | (3,151 | ) | 7,956 | 4,805 | 13,844 | 10,792 | 24,636 | |||||||||
Income from Continuing Operations | 71,759 | 14,162 | 85,921 | 44,485 | 17,890 | 62,375 | ||||||||||
Income (Loss) from Discontinued Operations, net | 13,337 | (825 | ) | 14,102 | (3,788 | ) | ||||||||||
(Loss) Gain on Disposition of Discontinued Operations, net | (4,537 | ) | (4,537 | ) | (467 | ) | (467 | ) | ||||||||
Net Income | 80,559 | 80,559 | 58,120 | 58,120 | ||||||||||||
Diluted Earnings (Loss) Per Share: | ||||||||||||||||
Continuing Operations | 0.55 | 0.11 | 0.66 | 0.34 | 0.14 | 0.48 | ||||||||||
Income (Loss) from Discontinued Operations, net | 0.10 | (0.01 | ) | 0.11 | (0.03 | ) | ||||||||||
(Loss) Gain on Disposition of Discontinued Operations, net | (0.04 | ) | (0.04 | ) | 0.00 | (0.00 | ) | |||||||||
Net Income Per Share | 0.62 | 0.62 | 0.45 | 0.45 | ||||||||||||
Weighted average diluted shares of common stock outstanding | 131,021 | 131,021 | 131,021 | 129,230 | 129,230 | 129,230 | ||||||||||
The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PERKINELMER, INC. | ||
| Date: December 15, 2005 | By: /s/ Robert F. Friel | |
Robert F. Friel Executive Vice President and Chief Financial Officer | ||